Phillip Broadwith
As Business editor, my aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping you abreast of trends and developments in the world of chemistry businesses.
From the point I left school, my aim was to join the pharmaceutical industry. A gap year and summer placements in company labs, and a PhD in organic synthesis followed.
But halfway through my PhD I entered a writing competition run by the Daily Telegraph. I managed to win – somewhat to my own surprise. That changed my perspective and made me think that I should consider writing more seriously as a career. I joined the Royal Society of Chemistry just before submitting my thesis, and luckily a position with Chemistry World came up a few months later. I sometimes miss the thrills (less so the spills) of lab work, but interacting with world-leading scientists and industrialists, as well as learning new things on a daily basis more than makes up for it.
Contact Info
- Email:
- broadwithp@rsc.org
BusinessGM corn growers win US lawsuit against Syngenta
Kansas jury awards over $217m damages to farmers in the first of eight trials
BusinessJ&J licenses Protagonist’s inflammatory bowel peptide
Potential first-in-class treatment is just about to enter clinical trials
BusinessExplosion kills 10 at Chinese petrochemical plant
Nine others injured when gas tanker exploded in loading area
BusinessIneos expands North Sea oil and gas operations
Purchase of Danish Dong Energy and BP’s Forties pipeline will feed Grangemouth refinery
OpinionDrug pricing must be more transparent
Pricing is a complex issue - how can we make it clearer?
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
BusinessPatheon buyout brings Thermo into contract manufacturing
$7.2bn deal expands Thermo Fisher’s laboratory products and services segment
BusinessSabic takes control of Shell petrochemicals joint venture
$820m sale of Saudi Arabian plants continues Shell’s global reorganisation programme
BusinessDaiichi Sankyo to close R&D sites in India and Japan
Closures are part of an ongoing reorganisation aimed at increasing productivity
BusinessAllergan to buy fat-freezing firm Zeltiq
$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
OpinionCollaboration and competition can both stimulate innovation
Diverse approaches suit different goals
BusinessJ&J to close Scottish medical device plant
Up to 400 positions affected as Ethicon subsidiary leaves Livingston
BusinessPacBio sues Oxford Nanopore for patent infringement
Firms spar over single-molecule gene sequencing technology
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
BusinessAnalytical data heads to the cloud
Many manufacturers were launching software instead of instruments at Pittcon
BusinessJob cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
OpinionBuilding business across borders
Internationality is here to stay. Companies need to capitalise on it
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
BusinessChina approves BMS’s hepatitis C drugs
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
BusinessBP to sell Chinese joint venture stake to Sinopec
Oil giant retains significant investment in China, but is shifting focus
